Bharat Biotech’s COVID-19 Vaccine has been authorized for clinical trials, rendering it India’s first domestic product to earn green light from the government drug regulator.
The company’s application for a Phase I and Phase II clinical trial of Cobaxin, which was developed together with the National Institute of Virology of the Indian Council of Medical Research, was approved by the Indian Drug Controller General on Monday.
The vaccine developed and manufactured in Bharat Biotech’s facility in Genome Valley, Hyderabad will start in July with human clinical trials across the country.
No commercial vaccine has already been approved for the novel coronavirus, but more than a dozen vaccines are being tested on humans from over 100 vaccine candidates worldwide.
The post India’s COVID-19 vaccine cleared for human trials appeared first on Insights Care.
This post first appeared on CRISPR-Cas9 Technology: A Potential Game Changer In Medicine., please read the originial post: here